{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:52:18Z","timestamp":1787025138330,"version":"build-2736575974"},"reference-count":41,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Epidemiological data on psoriasis in Norway are limited. The aim of this study was to provide objective national data on the incidence and prevalence of psoriasis. Patients registered in the Norwegian Prescription Database with a diagnostic code indicating psoriasis vulgaris on prescriptions were included. During the period 2004 to 2020, 272,725 patients received prescription for psoriasis vulgaris in Norway. During the period 2015 to 2020, 84,432 patients received prescription for psoriasis vulgaris for the first time. In 2020, 71,857 (97.7%) patients received topical, 7,197 (9.8%) conventional systemic and 2,886 (3.9%) biological medication for psoriasis vulgaris. In the period 2015 to 2020, the point prevalence of psoriasis was 3.8\u20134.6% and the incidence was 0.29\u20130.25%. Norway is divided into 4 geographical health regions. A latitudinal difference was observed between the 4 regions, highest in Northern Norway. In the incidence population, median age was 47\u201353 years and males comprised 46\u201350%. In this study of psoriasis vulgaris, prevalence in Norway was higher than in earlier reports from other countries. There was a small female predominance regarding incidence and prevalence; however, men had more prescriptions for systemic treatment. Prescriptions for psoriasis vulgaris showed a stable level, with a trend of increasing use of biological medication during the study period.<\/jats:p>","DOI":"10.2340\/actadv.v103.4591","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T07:37:10Z","timestamp":1681889830000},"page":"adv4591","source":"Crossref","is-referenced-by-count":8,"title":["Psoriasis in Norway: A Prescription-based Registry Study of Incidence and Prevalence"],"prefix":"10.2340","volume":"103","author":[{"given":"Silje Michelsen","family":"Solberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"key":"30858","doi-asserted-by":"crossref","unstructured":"Spronk I, Korevaar JC, Poos R, Davids R, Hilderink H, Schellevis FG, et al. Calculating incidence rates and prevalence proportions: not as simple as it seems. BMC Public Health 2019; 19: 512.","DOI":"10.1186\/s12889-019-6820-3"},{"key":"30859","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s12889-019-6820-3","DOI":"10.1186\/s12889-019-6820-3"},{"key":"30860","doi-asserted-by":"crossref","unstructured":"Modalsli EH, Snekvik I, Asvold BO, Romundstad PR, Naldi L, Saunes M. Validity of self-reported psoriasis in a general population: the HUNT Study, Norway. J Invest Dermatol 2016; 136: 323-325.","DOI":"10.1038\/JID.2015.386"},{"key":"30861","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/JID.2015.386","DOI":"10.1038\/JID.2015.386"},{"key":"30862","doi-asserted-by":"crossref","unstructured":"Danielsen K, Olsen AO, Wilsgaard T, Furberg AS. Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. Br J Dermatol 2013; 168: 1303-1310.","DOI":"10.1111\/bjd.12230"},{"key":"30863","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.12230","DOI":"10.1111\/bjd.12230"},{"key":"30864","doi-asserted-by":"crossref","unstructured":"Kavli G, Forde OH, Arnesen E, Stenvold SE. Psoriasis: familial predisposition and environmental factors. Br Med J (Clin Res Ed) 1985; 291: 999-1000.","DOI":"10.1136\/bmj.291.6501.999"},{"key":"30865","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmj.291.6501.999","DOI":"10.1136\/bmj.291.6501.999"},{"key":"30866","doi-asserted-by":"crossref","unstructured":"Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol 2010; 106: 86-94.","DOI":"10.1111\/j.1742-7843.2009.00494.x"},{"key":"30867","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1742-7843.2009.00494.x","DOI":"10.1111\/j.1742-7843.2009.00494.x"},{"key":"30868","doi-asserted-by":"crossref","unstructured":"Egeberg A, Skov L, Gislason GH, Thyssen JP, Mallbris L. Incidence and prevalence of psoriasis in Denmark. Acta Derm Venereol 2017; 97: 808-812.","DOI":"10.2340\/00015555-2672"},{"key":"30869","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-2672","DOI":"10.2340\/00015555-2672"},{"key":"30870","doi-asserted-by":"crossref","unstructured":"Lindberg I, Lilja M, Geale K, Tian H, Richardson C, Scott A, et al. Incidence of psoriatic arthritis in patients with skin psoriasis and associated risk factors: a retrospective population-based cohort study in Swedish routine clinical care. Acta Derm Venereol 2020; 100: adv00324.","DOI":"10.2340\/00015555-3682"},{"key":"30871","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-3682","DOI":"10.2340\/00015555-3682"},{"key":"30872","doi-asserted-by":"crossref","unstructured":"Gnjidic D, Du W, Pearson SA, Hilmer SN, Banks E. Ascertainment of self-reported prescription medication use compared with pharmaceutical claims data. Public Health Res Pract 2017; 27: 27341702.","DOI":"10.17061\/phrp27341702"},{"key":"30873","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.17061\/phrp27341702","DOI":"10.17061\/phrp27341702"},{"key":"30874","doi-asserted-by":"crossref","unstructured":"Svedbom A, Mallbris L, Larsson P, Nikamo P, Wolk K, Kjellman P, et al. Long-term outcomes and prognosis in new-onset psoriasis. JAMA Dermatol 2021; 157: 684-690.","DOI":"10.1001\/jamadermatol.2021.0734"},{"key":"30875","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2021.0734","DOI":"10.1001\/jamadermatol.2021.0734"},{"key":"30876","doi-asserted-by":"crossref","unstructured":"Desbiens NA. The reporting of statistics in medical educational studies: an observational study. BMC Med Res Methodol 2007; 7: 35.","DOI":"10.1186\/1471-2288-7-35"},{"key":"30877","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/1471-2288-7-35","DOI":"10.1186\/1471-2288-7-35"},{"key":"30878","doi-asserted-by":"crossref","unstructured":"Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-385.","DOI":"10.1038\/jid.2012.339"},{"key":"30879","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/jid.2012.339","DOI":"10.1038\/jid.2012.339"},{"key":"30880","doi-asserted-by":"crossref","unstructured":"Boehncke WH, Schon MP. Psoriasis. Lancet 2015; 386: 983-994.","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"30881","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(14)61909-7","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"30882","doi-asserted-by":"crossref","unstructured":"Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361: 496-509.","DOI":"10.1056\/NEJMra0804595"},{"key":"30883","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMra0804595","DOI":"10.1056\/NEJMra0804595"},{"key":"30884","unstructured":"Braathen LR, Botten G, Bjerkedal T. Prevalence of psoriasis in Norway. Acta Derm Venereol 1989; Suppl 142: 5-8."},{"key":"30885","doi-asserted-by":"crossref","unstructured":"Olsen AO, Grjibovski A, Magnus P, Tambs K, Harris JR. Psoriasis in Norway as observed in a population-based Norwegian twin panel. Br J Dermatol 2005; 153: 346-351.","DOI":"10.1111\/j.1365-2133.2005.06613.x"},{"key":"30886","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06613.x","DOI":"10.1111\/j.1365-2133.2005.06613.x"},{"key":"30887","doi-asserted-by":"crossref","unstructured":"Falk ES, Vandbakk O. Prevalence of psoriasis in a Norwegian Lapp population. Acta Derm Venereol 1993: 182: 6-9.","DOI":"10.2340\/0001555518269"},{"key":"30888","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/0001555518269","DOI":"10.2340\/0001555518269"},{"key":"30889","doi-asserted-by":"crossref","unstructured":"Danielsen K, Duvetorp A, Iversen L, Ostergaard M, Seifert O, Tveit KS, et al. Prevalence of psoriasis and psoriatic arthritis and patient perceptions of severity in Sweden, Norway and Denmark: results from the Nordic patient survey of psoriasis and psoriatic arthritis. Acta Derm Venereol 2019; 99: 18-25.","DOI":"10.2340\/00015555-3017"},{"key":"30890","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-3017","DOI":"10.2340\/00015555-3017"},{"key":"30891","doi-asserted-by":"crossref","unstructured":"Hagg D, Sundstrom A, Eriksson M, Schmitt-Egenolf M. Severity of psoriasis differs between men and women: a study of the clinical outcome measure psoriasis area and severity index (PASI) in 5438 Swedish register patients. Am J Clin Dermatol 2017; 18: 583-590.","DOI":"10.1007\/s40257-017-0274-0"},{"key":"30892","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40257-017-0274-0","DOI":"10.1007\/s40257-017-0274-0"},{"key":"30893","doi-asserted-by":"crossref","unstructured":"Snekvik I, Nilsen TIL, Romundstad PR, Saunes M. Psoriasis and cardiovascular disease risk factors: the HUNT study, Norway. J Eur Acad Dermatol Venereol 2018; 32: 776-782.","DOI":"10.1111\/jdv.14835"},{"key":"30894","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.14835","DOI":"10.1111\/jdv.14835"},{"key":"30895","doi-asserted-by":"crossref","unstructured":"Nast A, Smith C, Spuls PI, Valle GA, Bata-Csorgo Z, Boonen H, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol 2020; 34: 2461-2498.","DOI":"10.1111\/jdv.16915"},{"key":"30896","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.16915","DOI":"10.1111\/jdv.16915"},{"key":"30897","doi-asserted-by":"crossref","unstructured":"Tveit KS, Duvetorp A, Ostergaard M, Skov L, Danielsen K, Iversen L, et al. Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). J Eur Acad Dermatol Venereol 2019; 33: 340-354.","DOI":"10.1111\/jdv.15252"},{"key":"30898","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.15252","DOI":"10.1111\/jdv.15252"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/4591\/16077","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/4591\/16077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T07:38:31Z","timestamp":1681889911000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/4591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":41,"URL":"https:\/\/doi.org\/10.2340\/actadv.v103.4591","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,19]]}}}